Allergan enters bidding war for Shire; Opioid prescriptions drop in 2017; Novartis Q1 numbers disappoint.
Sanders introduces opioid bill; GW gets nod from FDA for Epidiolex; Sanofi sells generic unit to Advent for $2.4 billion.
J&J Q1 numbers beat expectations; Amazon scraps pharma product distribution plan; FDA works to develop regulatory processes for AI.
Shire sale of oncology business makes it more affordable for Takeda; FDA reverses course on Alkermes depression drug; Sorrell out as WPP CEO.
FDA investigates unapproved herpes vaccine; DC launches PReP campaign; J&J ordered to pay $80 million in damages in asbestos suit.
Alexion buys Wilson in latest pharma deal; Drug performance software company Aetion gets financial backing; Roche stops enrollment in combo study after patient deaths.
White House to allow states to determine health benefits required by Obamacare; FDA orders Essure sales restrictions; Researchers recommend redefining Alzheimer's.
Novartis to buy AveXis; Merck lung cancer drug meets primary goal in trial; "Pharma bro" duo expose more drug pricing flaws.
Facebook puts hospital patient data project on hold; Pharma companies' spending on advocacy under the microscope; Naloxone made more widely available.
Gottlieb asks for internet providers' help fighting opioid crisis; Ferring acquires Rebiotix; AbbVie reaches deal with Biogen to delay Humira rival.
Obamacare signup total misses 2017 numbers; Feds warn of "nightmare bacteria"; Lilly, startup reach $473 million deal on diabetes work.
Celgene COO exits; Study: Most Americans think ACA marketplaces are "collapsing"; Average payments to insurers to increase by more than expected in 2019.
FDA won't review Alkermes' depression drug; Nature Methods retracts paper on CRISPR; Eli Lilly's new R&D chief plans aggressive strategy.
PhRMA has released a series of new ads that blame high drug prices on cost increases to insurers and PBMs; Veterans Affairs Secretary Dr. David Shulkin has been fired; UK biotech Redx has suspended a Phase I/II trial of its cancer drug
Takeda considers Shire acquisition; Rite Aid transfers nearly 2,000 stores to Walgreens; Oscar raises $165 million in latest funding round.
GSK to buy out Novartis' stake in consumer healthcare partnership; Aetna to pass on prescription drug rebates to members; California drug price transparency law shows results.
Ablynx drops vobarilizumab; Investors unimpressed by Biohaven migraine drug meeting benchmarks; Trump administration prison anti-opioid push relies on naltrexone.
GSK yanks bid for Pfizer consumer health business; Latest government spending bill includes more for FDA; Chantix fails teen study.
Anti-opioid-abuse funding in federal budget bill, healthcare market stabilization out; Redfield tapped to lead CDC; Healthcare companies look to pharma for leadership.
J&J CFO plans September retirement; GSK pharma chief to turn business towards oncology, immunology; MM&M unveils 2018 list of healthcare transformers, innovation catalysts.
Roche's immunotherapy Tecentriq, when combined with a Abraxane-based chemo, decreased the risk of disease worsening or death compared to chemo alone in first-line patients with advanced squamous non-small cell lung cancer; President Trump spoke about using federal prosecutors to sue opioid makers; Trump also vowed to bring down the cost of prescription drugs.
Congress has spent less than a quarter of the $500 million to fight the opioid epidemic; The #MeToo movement is gaining steam in the medical industry; Dr. Robert R. Redfield, a leading AIDS researcher, is the top candidate to lead the Centers for Disease Control and Prevention.
Pfizer persuades Read to stay another year; House GOP to take another crack at "right to try"; Lundbeck plans to acquire Prexton Therapeutics.
FDA moves to limit nicotine in cigarettes; Alexion reports positive test for rare blood disorder treatment; Oregon governor signs drug pricing transparency bill.
Why the U.S. spends more on healthcare with worse results; Alnylam goes it alone on rare disease therapy; MorphoSys hopes for accelerated approval on MOR208.
UnitedHealth names Witty as Optum CEO; Gilead R&D chief to exit; Novartis ups chief digital officer to executive committee.
Regeneron, Sanofi cut cost of Praluent for wider coverage; GSK to maintain Advair exclusivity for 2018; 'Right to try' bill introduced in House.
White House quashes Idaho's insurance plans; Voyager reports positive results in clinical trial for Parkinson's drug; Cigna-Express Scripts deal to face long review.
Cigna to buy Express Scripts for $52B; Gottlieb says 'rigged' system is keeping drug prices high; Sanofi, Evotec speed up infectious disease research.
UnitedHealth to pass on rebates to customers; Arkansas adds Medicaid work requirements; American College of Physicians reveals Type 2 diabetes guidelines.